Biotechnology
YS Biopharma Announces Name Change to LakeShore Biopharma
GAITHERSBURG, Md., May 24, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseas...
2024-05-24 19:30
2009
Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting
* The ELECTRA and ELEVATE studies were designed to overcome different resistance mechanisms and improve patient outcomes with oral-oral combination options. * Updated results from the ELECTRA study, evaluating elacestrant in combination with abemaciclib regardless of metastatic site,show a sa...
2024-05-24 17:36
2547
Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a Selective and Orally Bioavailable KRAS G12D Inhibitor
SHANGHAI, May 24, 2024 /PRNewswire/ -- Tyligand Bioscience, a clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies, announced that the first patient had been dosed in the Phase 1/2 trial of TSN1611 for the treatment of KRAS G12D mutant solid...
2024-05-24 16:33
1804
Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
* Anittumor efficacy of sunvozertinib was observed in patients regardless of baseline EGFR exon20ins status in plasma ctDNA. * Sunvozertinib could effectively clear EGFR exon20ins in plasma ctDNA, confirming its direct effect on EGFR pathway. * The resistance to sunvozertinib could be thro...
2024-05-24 16:32
1770
CStone Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website
* CS5001 is the first known ROR1 antibody-drug conjugate (ADC) to demonstrate clinical anti-tumor activity in both solid tumors and lymphomas, and among the top two globally in clinical development. * First-in-human study data show that CS5001 is well tolerated with promising anti-tumor activ...
2024-05-24 13:00
2265
ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates
SUZHOU, China and ROCKVILLE, Md., May 23, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that its four abstracts selected for presentations a...
2024-05-24 09:15
1822
Antengene To Present One Oral and Four Abstracts at ASCO 2024
* Oral Presentation：a Phase II study of ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody in patients with cervical cancer * Three Poster presentations: Phase I/II studies of ATG-031 (anti-CD24 monoclonal antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), and selinexor(XPO1 Inh...
2024-05-24 08:30
2882
Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024
Phase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium expression, including in patients with PD-L1 CPS<5. PRINCETON, N.J. and SUZHOU, China, May 24, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharm...
2024-05-24 08:00
2317
Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024
Phase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium expression, including in patients with PD-L1 CPS<5. PRINCETON, N.J. and SUZHOU, China, May 23, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharm...
2024-05-24 08:00
2155
ONCOCLÍNICAS APPROVES R$ 1.5 BILLION CAPITAL INCREASE
Operation aims to strengthen the Company's financial position and maintain growth strategy SAO PAULO, May 24, 2024 /PRNewswire/ -- Oncoclínicas&Co (B3: ONCO3), a leading oncology company headquartered inLatin America, has announced that the enterprise has approved a capital increase ofR$ 1.5 bil...
2024-05-24 06:41
1956
Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at ASGCT 2024
SUZHOU, China, May 23, 2024 /PRNewswire/ -- On May 10, 2024, Cure Genetics announced the safety and efficacy data of their CAR-NKT product, CGC729, for patients with relapsed and refractory metastatic renal cell carcinoma (R/R mRCC) in an oral presentation at the 27th Annual Meeting of the Americ...
2024-05-23 23:00
2187
Providence and Ontario Institute for Cancer Research (OICR) partnering to discover and develop mRNA therapeutics
CALGARY, AB and TORONTO, May 23, 2024 /PRNewswire/ -- Providence Therapeutic Holdings Inc. ("Providence"), a messenger RNA (mRNA) and lipid nanoparticle platform company engaged in the development of vaccines and therapeutics, and the Ontario Institute for Cancer Research (OICR),Ontario's largest...
2024-05-23 21:05
1347
Complete Genomics opens U.S. supply chain to genomic sequencing customers through a new manufacturing facility at its San Jose, Calif. headquarters
SAN JOSE, Calif., May 23, 2024 /PRNewswire/ -- Complete Genomics, a pioneering genomic sequencing company, recently welcomed vendors, suppliers, customers and employees to aMay 17 grand opening celebration of its 10,115 square foot manufacturing facility at its headquarters inSan Jose, California...
2024-05-23 21:00
1507
MediThinQ Unveils SCOPEYE 3D Micro Surgery Solution; Chris Lee of VentureBlick Assumes Chairmanship
SINGAPORE, May 23, 2024 /PRNewswire/ -- MediThinQ, the Korean startup pioneering extended reality (XR) wearable displays for surgical applications, unveils its groundbreaking SCOPEYE 3D Micro Surgery Solution. This innovative microsurgery solution leverages the latest Eyes Up Display technology t...
2024-05-23 10:00
14102
PharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops from its Proprietary OPC Platform at ARVO 2024
* Presentation at ARVO 2024 gained attention as Eylea (aflibercept) eye drops demonstrated similar efficacy to intravitreal injections in animal studies. DAEJEON, South Korea , May 22, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ:208340), a clinical-stage publ...
2024-05-23 08:51
1570
Bionoxx to Highlight Innovative Strategy for Addressing Immune-Related Diseases at 2024 BIO International Conference
Corporate presentation scheduled for Tuesday, 04 June 2024 at 4:00 PM PT SAN DIEGO and SEOUL, South Korea, May 23, 2024 /PRNewswire/ -- Bionoxx Inc., an innovative biotech company developing neutrophil-directed T cell modulation technology, announced today it will unveil its novel immunomodulator...
2024-05-23 08:00
1936
Further CYP-001 GvHD Clinical Data Published in Nature Medicine
Two-year overall survival rate in patients with steroid-resistant acute GvHD was 60% MELBOURNE, Australia, May 23, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to an...
2024-05-23 07:53
1659
Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies
CAMBRIDGE, Mass., May 22, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research, announced today that it has entered into a license agreemen...
2024-05-23 07:23
1454
Aiming for New Quality Productivity, Aiding in Reaching the Summit of Global Innovative Pharmaceuticals
Fully Human Antibody Development Platform—NeoMab Bio Officially Opens in Suzhou SUZHOU, China, May 22, 2024 /PRNewswire/ -- On May 22, 2024, NeoMab Biotechnology (Suzhou) Co., Ltd. celebrated its grand opening in Suzhou Industrial Park (BioBAY). This marks a significant milestone that will furthe...
2024-05-22 22:38
1881
Lunit Completes Acquisition of Volpara: Pioneering Next-Level of AI-Driven Cancer Care
SEOUL, South Korea, May 22, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, proudly announces the successful completion of its acquisition of Volpara Health Technologies, a global leader in medical software for breast...
2024-05-22 21:00
2062
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5216
